EPAX Sales Well Ahead of 2005 Pace

FLORIDA, N.Y.—Pharmline Inc. reported sales of EPAX® AS concentrates are tracking at over 40-percent ahead of the same time period last year.The company noted the omega-3 EFA (essential fatty acid) category has experienced double-digit growth rates for the past five years and is projected to grow at rates of 8 percent, on average, into 2010 (Frost & Sullivan). The company attributes the exceptional performance to EPAX AS’s commitment to manufacturing marinebased omega-3 EFAs that exceed the standards for purity in the industry. Contributing to the growth are successful new products— including EPAX 6015 (both Ethyl Ester (EE) and Triglyceride (TG) forms), which delivers 530 mg/g EPA and 100 mg/g DHA—as well as exclusive and innovative purification technology ensuring products will consistently meet or exceed all known global purity standards.

For more information on Pharmline, visit www.pharmlineinc.com; the company is a sponsor at SupplySide West. For more information on EPAX, visit www.epax.com or Booth #7021-7023 at SupplySide West.